Bullish
Johnson & Johnson's Ottava Surgical Robot Receives FDA Approval, Stock Rises Nearly 2%
Johnson & Johnson's Ottava surgical robot has received FDA marketing authorization, marking the company's entry into the soft-tissue robotic-assisted surgery market. This development has positively impacted the stock, which rose nearly 2% following the announcement.
Key points
- Ottava Surgical Robot Receives FDA Approval
- Insider Sells $5.79 Million in Shares
- Institutional Investors Adjust Holdings
Sources
- Johnson & Johnson's Ottava Surgical Robot Receives FDA Marketing Authorization, Stock Rises Nearly 2%VCBeat · July 23, 2026
- Johnson & Johnson (JNJ) Executive Sells Over $5.79 Million in SharesGuruFocus · July 25, 2026
- Arrowstreet Capital Limited Partnership Sells 1,504,237 Shares of Johnson & Johnson $JNJMarketBeat · July 25, 2026
AI-generated from public news sources. Not financial advice.
